Sep 7, 2021 7:00am EDT Tonix Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
Aug 24, 2021 7:00am EDT Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC)
Aug 9, 2021 4:45pm EDT Tonix Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights
Aug 2, 2021 7:00am EDT Tonix Pharmaceuticals Announces Groundbreaking Ceremony for Massachusetts R&D Facility to House the Advanced Development Center (ADC) for Vaccine Programs
Jul 27, 2021 7:00am EDT Tonix Pharmaceuticals Announces Agreement to Acquire Infectious Disease R&D Facility to Accelerate Development of Vaccines and Antiviral Drugs
Jul 23, 2021 4:40pm EDT Tonix Pharmaceuticals Announces Outcome of Interim Analysis of Phase 3 RALLY Study of TNX-102 SL for the Management of Fibromyalgia
Jun 21, 2021 7:00am EDT Tonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC)
